Cytopoint is being promoted as a revolutionary, safe solution for dogs suffering from itchy skin conditions. Veterinarians are often told it’s not a pharmaceutical and therefore poses no risk. However, a closer examination reveals a more complex reality. This article delves into what Cytopoint truly is, how it works, its potential side effects, and why caution is strongly advised.
Understanding Cytopoint: More Than Just a “Wonder Drug”
Cytopoint is part of a new class of treatments, and while its manufacturer may dispute the term, it is indeed a drug. It is an artificially synthesized substance administered via injection, designed to alter physiological functions, specifically targeting the immune system. Unlike traditional chemical-based pharmaceuticals, Cytopoint is a synthetic monoclonal antibody. Antibodies are proteins naturally produced by the body to combat antigens like viruses and bacteria. They neutralize these foreign substances and can activate the complement system to destroy pathogens.
The Complex Role of Cytokines
Cytokines are small proteins crucial for numerous bodily functions. They are produced by various cells and form complex signaling pathways called cytokine cascades. These proteins are not limited to a single function; they are multifunctional and regulate diverse physiological processes across different sites in the body. One such important cytokine is Interleukin 31 (IL-31).
Interleukin 31 (IL-31) and Its Functions
Produced by T helper cells, mast cells, macrophages, and dendritic cells, IL-31 primarily acts on the skin, lungs, intestines, and nervous system. Its main role is to trigger cell-mediated immunity against pathogens, meaning blocking IL-31 could potentially increase a dog’s susceptibility to infections. Furthermore, IL-31 is involved in regulating red blood cell homeostasis and connective tissues. Blocking this cytokine might contribute to conditions like immune-mediated hemolytic anemia (IMHA) and neuro-fascial pain. IL-31 also plays a part in the connection between the immune and sensory nervous systems, influencing cell proliferation and differentiation. Consequently, its suppression could lead to immune system dysregulation and even raise concerns about accelerating tumor growth. Elevated IL-31 levels are associated with the chronic itch of atopy, which is why Cytopoint was developed to target and block it.
Potential Side Effects and Safety Concerns of Cytopoint
Despite assurances of safety, evidence suggests Cytopoint can cause significant side effects. Online searches reveal numerous accounts of dogs experiencing severe adverse reactions shortly after Cytopoint injections. These reactions can occur after the first dose or after several treatments. Tragically, there are reports of dogs dying, along with a worrying number of gastrointestinal issues and even epilepsy. Some dogs become generally unwell, experience increased pain, or develop serious autoimmune diseases, including IMHA, shortly after treatment.
Is Cytopoint Truly Safe?
From a veterinary perspective, Cytopoint is not considered safe. Its mechanism of blocking a vital communication pathway within the body can lead to severe, unintended consequences. Blocking a single, critical component of immune function can disrupt the entire system, potentially causing widespread damage akin to a blocked oil pipe in a car engine leading to total motor failure.
Debunking Cytopoint’s Claims
The claims made about Cytopoint warrant closer scrutiny:
- “Not an immunosuppressant”: While not a blanket immunosuppressant like cortisone or Apoquel, Cytopoint does suppress a specific, important aspect of immune function – IL-31 signaling. This suppression impacts all cytokine cascades involving IL-31, leading to broader immune system dysregulation.
- “Not a pharmaceutical”: Cytopoint is a man-made monoclonal antibody. While not a chemical drug in the traditional sense, it functions as a pharmaceutical by attempting to “cure” a symptom (itch) by targeting a single bodily function, without addressing the root cause of the imbalance.
- “Safe for dogs”: The safety claims are largely based on limited studies involving lab beagles, which may not be representative of the wider dog population. The anecdotal evidence of harm and death suggests Cytopoint is far from universally safe.
Given these concerns, avoiding Cytopoint and exploring safer, natural alternatives is strongly recommended.
Frequently Asked Questions About Cytopoint
How much does a Cytopoint shot cost?
The cost typically ranges from $50 to $150 per injection, varying by location and clinic. However, potential risks should be weighed against the financial cost.
How long can a dog stay on Cytopoint?
Cytopoint injections are usually administered every 4 to 8 weeks for itch relief. However, the long-term impact on the immune system necessitates cautious evaluation and discussion of safer alternatives with your veterinarian.
Is Cytopoint better than Apoquel?
Both Cytopoint and Apoquel aim to manage itchiness without addressing the root cause of allergies. Cytopoint targets IL-31, while Apoquel is an immunosuppressant. Both have significant risks and potential for immune system disruption.
Is Cytopoint a steroid?
No, Cytopoint is not a steroid. It is a monoclonal antibody that targets IL-31. However, it still significantly impacts the immune system, carrying its own set of risks.
References
Gonzales AJ et al. Interleukin-31: Its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53.
Olivry T, Bäumer W. Atopic itch in dogs: Pharmacology and modeling. Pharmacology of Itch. 205;226:357-69.
Marsella R, Sousa CA, Gonzales AJ, et al. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc. 2012;241(2):194-207.
Olivry T et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21(3):233-248.
Hawro T et al. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy. 2014 Jan;69(1):113-7.
Christian Cornelissen et al. Signaling by IL-31 and functional consequences. European Journal of Cell Biology. 2012;91(6-7):552-66.
Floege J, Lüscher B, Müller-Newen G. Molecular mechanisms of cytokin-mediated inflammatory processes: Signal transduction and pathophysiological consequences. European Journal of Cell Biology. 2012;91(6–7):552-66.